Published in Surgery Litigation and Law Weekly, November 24th, 2006
The increase in product revenues was primarily due to a significant increase in demand for the company's flagship reconstructive surgical product, AlloDerm Regenerative Tissue Matrix, which increased 55% to $29.9 million in the current quarter compared to $19.3 million in the third quarter of 2005. Orthopedic product revenues, which include Graft Jacket and AlloCraftDBM, increased to $2.4 million in the quarter from $2.0 million in the third...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly